Journals / Epilepsi / 2015 / Cilt: 21 - Sayı: 1

Epileptik Yetişkinlerde Parsiyel Başlangıçlı Nöbet Tedavisinde Ek Lakosamit Tedavisi: Bir Derleme

Partial Onset Seizure Treatment with Adjunctive Lacosamide in Epileptic Adults: A Review

Journal
Epilepsi
Pages
1–5
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results revealed that LCM is well tolerated and effective in seizure reduction as adjunctive therapy in patients with uncontrolled partial-onset seizures.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Epilepsy is a common chronic disorder of the brain and can be seen at all ages with a higher prevalence in developing countries.
📊
Key Findings & Data:Recently 3 Phase II/III placebo controlled clinical trials with similar designs were conducted to investigate the efficacy and safety of lacosamide (LCM) administered as adjunctive therapy with other AEDs.
💡
Conclusion & Impact:Results revealed that LCM is well tolerated and effective in seizure reduction as adjunctive therapy in patients with uncontrolled partial-onset seizures.
🔬Design:Lab & Field Experiment
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Epilepsy is a common chronic disorder of the brain and can be seen at all ages with a higher prevalence in developing countries. Adjunctive therapy with antiepileptic drugs (AEDs) is the gold standard in treatment of epilepsy. Lacosamide (LCM) is a novel AED which is approved for adjunctive therapy for the treatment of partial-onset seizures. Recently 3 Phase II/III placebo controlled clinical trials with similar designs were conducted to investigate the efficacy and safety of lacosamide (LCM) administered as adjunctive therapy with other AEDs. Data collected from those studies were pooled, re-analyzed and presented in this review article. Results revealed that LCM is well tolerated and effective in seizure reduction as adjunctive therapy in patients with uncontrolled partial-onset seizures.

Özet

Epilepsi sık görülen, kronik, serebral bir hastalıktır ve daha çok gelişmekte olan ülkelerde, her yaştaki bireyde karşımıza çıkabilir. Günümüzde antiepileptik ilaçlar (AEİ) ile adjunktif tedavi epilepsi tedavisinde standart olarak uygulanmaktadır. Lakosamit (LCM) parsiyel başlangıçlı nö- betlerin adjunktif tedavisinde kullanımı için onay almış bir AEİ’tır. Yakın zamanda LCM’in etkililiğini ve güvenliliğini araştırmak amacıyla, diğer AEİ’lar ile beraber adjunktif tedavi olarak LCM’in uygulandığı, benzer tasarımlı, plasebo-kontrollü faz II/III klinik çalışmalar gerçekleştirilmiştir. Bu çalışmalardan elde edilen veriler ile bir veri havuzu oluşturulmuş ve üç çalışmadan toplanan bu veriler yeniden analiz edilmiş ve bu derlemede sunulmaktadır. Sonuçlar LCM’in iyi tolere edildiğini ayrıca kontrolsüz parsiyel başlangıçlı nöbetleri olan hastalarda nöbetlerin görülme sıklığını azalttığını ortaya koymuştur.

🔖

Cite This Article

MENACHEM, E. B. (2015). Epileptik Yetişkinlerde Parsiyel Başlangıçlı Nöbet Tedavisinde Ek Lakosamit Tedavisi: Bir Derleme. Epilepsi, Cilt: 21 - Sayı: 1, 1–5. https://ajindex.com/articles/161388

References (14)

  1. Online: World Health Organization (WHO). Available at: http:// www.who.int/mediacentre/factsheets/fs999/en/ (Date of access:17 November 2014
  2. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 1993;34(3):453-68
  3. Hauser A. Incidence and Prevalence in Epilpesy: A comprehensive textbook. Philadelphia, PA: Lippincot Raven; 1998. p. 47-57
  4. Online: Epilepsy Foundation. Available at: http://www.epilepsy.com/learn/epilepsy-statistics (Date of access:17 November 2014) 5. de Bittencourt PR, Adamolekum B, Bharucha N, Carpio A, Cossío OH, Danesi MA, et al. Epilepsy in the tropics: I. Epidemiology, socioeconomic risk factors, and etiology. Epilepsia 1996;37(11):1121-7
  5. Velioglu SK, Bakirdemir M, Can G, Topbas M. Prevalence of epilepsy in northeast Turkey. Epileptic Disord 2010;12(1):22-37
  6. Calişir N, Bora I, Irgil E, Boz M. Prevalence of epilepsy in Bursa city center, an urban area of Turkey. Epilepsia 2006;47(10):1691-9
  7. French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62(8):1261-73
  8. VIMPAT® (lacosamide). Summary of Product Characteristics. UCB, 25 October 2010
  9. Beydoun A, D’Souza J, Hebert D, Doty P. Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures. Expert Rev Neurother 2009;9(1):33-42
  10. Errington AC, Stöhr T, Heers C, Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 2008;73(1):157-69
  11. Niespodziany I, Leclère N, Vandenplas C, et al. Comparative study of lacosamide with classic sodium channel blocking antiepileptic drugs on sodium current slow inactivation. Poster presented at the 9th European Congress on Epileptology, Rhodes 2010
  12. Jatuzis D, Biton V, Ben-Menachem E, et al; and the SP667 Study Group. Evaluation of the effect of oral lacosamide on adjunctive concomitant antiepileptic drug plasma concentrations in subjects with partial seizures. Poster presented at the 10th Congress of the European Federation of Neurological Societies, Glasgow 2006
  13. UCB Pharma SA. Data on file
  14. Rosenfeld W, Rud